



## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**Manuscript NO:** 64577

**Title:** Viral Hepatitis: milestones, unresolved issues, and future goals

**Reviewer's code:** 03646974

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Chief Doctor, Chief Physician

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2021-02-27

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-02-28 06:40

**Reviewer performed review:** 2021-03-07 11:35

**Review time:** 7 Days and 4 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input checked="" type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear authors, I carefully read the manuscript, 'Viral Hepatitis: milestones, unresolved issues, and future goals', and commented as follows: The author reviewed viral hepatitis C, viral hepatitis B, viral hepatitis D, viral hepatitis A, and viral hepatitis E. In the chapter on viral hepatitis C, authors focused on the current antiviral treatments and introduced treatment options for refractory hepatitis C. In the second chapter of viral hepatitis B and D, authors focus on new drugs for treating hepatitis D. In the third and fourth chapters, authors introduce the pathogenesis and treatment of hepatitis A and hepatitis E, respectively. In the study of hepatitis C and hepatitis D, more European literatures are cited. Compared with Asians, it is more difficult for Caucasians to treat hepatitis C. Italians may have a higher rate of hepatitis D infection. The literatures show that for treating patient with hepatitis B, the interferon response rate in the Asian population is significantly lower than that in the Caucasian; the nucleot(s)ide resistant mutation in Asian population is higher than other races. These differences are caused by genetic differences between Caucasians with Asians. Thus, the physicians in the Asia-Pacific region who read this article may cause confusion. There is no need to modify the manuscript in response to the above comments. Agree to accept the paper. Mini error: The first line on page 21, intravenous administration, should be changed to subcutaneous injection. Dr. Yin GQ